A new startup, Truveta, is looking to improve healthcare for patients and care facilities in 40 states in relation to the pandemic through the use of anonymous data from patients, a company blog post written by ex-Microsoft exec Terry Myerson stated.
The effort will also encompass research on some questions, particularly around COVID-19, according to the post.
“Which medications are most effective?” the post stated. When should patients be intubated? Why do African-American men have significantly higher mortality rates? In the U.S., why are nearly one-third of the nurses who died of COVID-19 Filipino, even though they represent 4 percent of the nursing population? What are the effects of COVID-19 and related isolation on adolescents and their mental health?”
Truveta asserted in the post that it will boost innovation in care and develop new therapies through the creation of the Truveta data program, which will classify data across both structured and unstructured platforms across all diagnoses, geographies and demographics.
Through advanced artificial intelligence (AI) and machine learning (ML), Truveta said in the post that it plans to deliver information for physicians, biopharma and families, through “aggregate analysis of conditions, therapies and prognoses.”
As health data is private, all of it will be used anonymously, according to the post.
The post asserted that Truveta is also working to help underserved populations that haven’t had access to healthcare. In addition, the company promised to safeguard patient data, helping with “structuring, normalizing, machine learning and visualizing” the data.
“Our vision is to save lives with data,” the post stated. “We want to help researchers find cures faster, empower every clinician to be an expert, and help families make the most informed decisions on their care.”
PYMNTS reported that the practices of data collecting are being reviewed to find the best and safest ways to handle information digitally as every institution shifts to online models to help mitigate virus spread. That comes as patients have largely done away with traditional in-person visits in lieu of digital ones to help stop the transmission.
The problems with authenticating customers digitally comes with the large size of the U.S. market. However, there are new technologies like biometrics to help accurately verify information.